Profitelligence Profitelligence · Filing Ledger Open TECH research →

Form 8-K · Current Report · Filed 2024-11-05

Bio-Techne Corporation Granted Restricted Stock Unit Award to CFO

On October 30, 2024, Bio-Techne Corporation's Compensation Committee granted James Hippel, the Company's Executive Vice President and Chief Financial Officer, a one-time restricted stock unit award of 34,634 shares.

Filer
Bio-Techne Corporation TECH · NASDAQ
Filed
Accession
0001558370-24-014442
CIK
0000842023
Signal
Low impactHealthcare

Details

The award is part of the Company's 2020 Equity Incentive Plan and will vest in equal installments over the first three anniversaries of the grant date, subject to Mr. Hippel's continued service with the Company.

Items reported

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

No viable tag
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$75.90

Next session

-0.1%

Since filing

-5.0%

Latest close

$72.09

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from TECH reporting the same item, with the next session's move:

About Bio-Techne Corporation

Bio-Techne Corporation is a leading developer and manufacturer of high-quality biological products and solutions for the research and clinical diagnostic markets. The company specializes in providing an extensive range of biotechnological tools that support the advancement of life sciences. Key offerings include proteins, antibodies, assay kits, and laboratory services critical for scientific research and drug development. Bio-Techne operates across diverse sectors such as biotechnology, pharmaceuticals, academic research, and healthcare, supplying innovative solutions that facilitate groundbreaking research and therapeutic discoveries. Its products are essential in advancing modern biology and medicine, contributing to significant developments in areas like cancer research, immunology, and cell biology. Bio-Techne’s commitment to innovation and quality makes it a pivotal player in the biotechnology industry, elevating scientific discovery and fostering advancements in personalized medicine and diagnostics. With a strong global presence, Bio-Techne continues to impact the global life sciences landscape profoundly, upholding a legacy of excellence and reliability in the biotechnological sector.

Exchange NASDAQ Industry Biotechnology Company website ↗

Never miss another TECH filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts